These data revealed the underlying mechanism of the EC protection conferred by rosuvastatin during atherosclerosis, which may be explained by the inhibition of Ang II involved in the Pyk2/MCU pathway activation, then decreasing intracellular ROS production and Ca2+ influx, protecting the mitochondrial function and ultimately preventing EC apoptosis (Figure 8G). Here, MCU is linked to atherosclerosis.